Information Provided By:
Fly News Breaks for November 21, 2018
NBIX
Nov 21, 2018 | 07:56 EDT
Canaccord analyst Sumant Kulkarni initiated Neurocrine with a Buy rating as he said the company is one of the few where a product launch exceeded expectations. He said he is guardedly optimistic heading into Phase 2b data for Ingrezza in pediatric Tourette syndrome and with the stock's recent pullback, he sees an attractive entry point. He also thinks the pullback could cause investors to look at Neurocrine to be involved in industry consolidation. Kulkarni set a $111 price target on Neurocrine shares.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.